Managing drug interactions in the patient with aspergillosis

References

• Kashuba DM, Bertino JS. Mechanisms of drug interactions. Drug Interactions in Infectious Diseases, SC Piscitelli, KA Rodvold. Humana Press, Totowa, NJ 2001; 13–38
   Google Scholar
• Gubbins PO, McConnell SA, Penzak SR. Antifungal Agents. Drug Interactions in Infectious Diseases, SC Piscitelli, KA Rodvold. Humana Press, Totowa, NJ 2001; 185–217
   Google Scholar
• Groll A, Walsh TJ. Pharmacology of antifungal compounds. Adv Pharmacol 1998; 44: 343–500
   PubMedGoogle Scholar
• Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine 1994; 330: 263–272
   PubMed Web of Science ®Google Scholar
• Heykants J, Michiels M, Meuldermans W, . The pharmacokinetics of itraconazole in animals and man: an overview. Recent trends in the discovery, development and evaluation of antifungal agents, RA Fromtling, et al. J. R. Prous Science Publishers, BarcelonaSpain 1987; 1–29
   Google Scholar
• Hoeschele JD, Roy AK, Pecoraro VL, et al. In vivo analysis of the interaction between sucralfate and ketoconazole. Antimicrobial Agents and Chemotherapy 1994; 38: 319–325
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Baciewicz FA. Ketoconazole and fluconazole drug interactions. Archives of Internal Medicine 1993; 153: 1970–1976
   PubMedGoogle Scholar
• Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: The effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998; 16: 33–37
   PubMed Web of Science ®Google Scholar
• Lim SG, Sawyerr AM, Hudson M, et al. Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Alimentary Pharmacology & Therapeutics 1993; 7: 317–321
   PubMed Web of Science ®Google Scholar
• Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003; 51: 453–457
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–637
   PubMed Web of Science ®Google Scholar
• Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48: 804–808
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645–653
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218–222
   PubMed Web of Science ®Google Scholar
• Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46: 160–165
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–134
   PubMed Web of Science ®Google Scholar
• Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62: 25–31
   PubMed Web of Science ®Google Scholar
• Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161–166
   PubMedGoogle Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788–2795
   PubMed Web of Science ®Google Scholar
• Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947–55
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587–588
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Crowe HM, Nightingale CH, et al. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29: 994–996
   PubMed Web of Science ®Google Scholar
• Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Safety 1993; 9: 309–311
   PubMed Web of Science ®Google Scholar
• Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58: 617–624
   PubMed Web of Science ®Google Scholar
• Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003; 33(Suppl 2)1–5
   PubMed Web of Science ®Google Scholar
• Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33: 676–682
   PubMed Web of Science ®Google Scholar
• Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Report of three cases. Am Rev Respir Dis 1971; 103: 831–841
   PubMed Web of Science ®Google Scholar
• The Institute of Medicine. To err is human: Building a safer health system. WashingtonDC: National Academy Press; 2000.
   Google Scholar
• Owens RC, Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004; 64: 1091–1124
   PubMed Web of Science ®Google Scholar
• Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 2004; 12: 222–234
   PubMedGoogle Scholar
• Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000; 36: 1–12
   PubMed Web of Science ®Google Scholar
• Ballidon R, Patterson T, Boucher HW. NDA 21-266, Vfend (voriconazole) tablets, and NDA 21-267, Vfend I.V. (voriconazole) for infusion, 2001. Available online at http://www.fda.gov/ohrms/dockets/ac/o1/slides/3792s2.htm (accessed 10 March 2003).
   Google Scholar
• Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 128–134
   PubMed Web of Science ®Google Scholar
• Summers KK, Hardin TC, Gore SJ, et al. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997; 40: 753–764
   PubMed Web of Science ®Google Scholar